Veterinary

 

 

With the animal vaccines market predicted to be worth $8.6 billion by 2018, can you really afford not to be a core service provider for these manufacturers? An increased focus on zoonotic infectious diseases and more attention towards the economic impact of disease in livestock of economic importance, make it clear why veterinary vaccines are coming into the limelight. This event will provide a platform for you to showcase how you are moving veterinary vaccine development methods forward, from technology to regulation and manufacture.

 

2018 AGENDA

 

Veterinary, Wednesday 4 April 2018

One Health

Dr Mahesh Kumar
Veterinary
09:10

Rational design of veterinary vaccines, is it less established than human vaccines?

  • Strategy when conventional vaccines don’t work
  • Can vaccines alone eradicate? The need to combine treatments outside of vaccines with alternative approaches
Professor Klaus Osterrieder
Veterinary
09:40

Vectored herpesvirus vaccines and novel approaches, for their attenuation and continued efficacy

Veterinary
10:10

Controlling zoonotic diseases in the developing world

10:40

Networking coffee break

Immune Enhancers & Vaccine Technology

Dr Robert Zolynas
Veterinary
11:40

Immunomodulators: Rationale for targeting the innate immune response when vaccines aren’t effective

  • Role of innate immunity
  • Immunostimulants as preventative and therapeutic agents
  • Recent developments in veterinary immunomodulators
Dr Jeffrey Ulmer
Veterinary
12:10

Self-amplifying RNA technology

Dr Jens Gertow
Veterinary
12:40

ELISpot and FluoroSpot in veterinary vaccine research

  • T-cell ELISpot assays and B-cell ELISpot assays in veterinary vaccine research
  • Novel potential of T and B-cell FluoroSpot assays in veterinary vaccine research
  • Why FluoroSpot and not intracellular cytokine staining and Flow cytometry?
Session led by: mabtech
1:10

Networking Lunch & Poster Session

Delivery and Manufacturing

Veterinary
2:40

The need to mass inoculate: What delivery systems have we developed that can cater for the different animal groups?

Alan Young
Veterinary
3:10

Bench to Market: Challenges and opportunities in the commercialization of academic vaccine candidates to the marketplace

Dr Darrel Styles
Veterinary
3:40

The role of veterinary vaccines in the emergency management of a foreign animal disease outbreak

4:10

Networking coffee break

Professor Thomas Geisbert
Veterinary
4:40

The need for a Nipah virus (NiV) vaccine - What are the challenges and why now?

  • Current platform review of soluble glycoprotein vaccines and virus vector platforms
  • Exact correlates of protection against NiV have not been completely defined
  • Sporadic nature of NiV outbreaks makes large scale Phase III clinical trials difficult to plan - how will we overcome this?
Veterinary
5:10

Mucosal PRRSV vaccine for swine

Dr Rhonda LaFleur
Veterinary
5:40

Nobivac® canine flu bivalent vaccine

  • Merck Animal Health’s response to CIV H3N2 outbreak in Chicago
  • CIV H3N2 infection in dogs
  • First vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8
  • Efficacy study results
  • Next steps
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 14/Dec/17 14:05

Veterinary, Thursday 5 April 2018

The role of vaccines in preventing AMR

Kemal Karaca
Veterinary
09:10

Role of vaccines in preventing further AMR - The big push

  • What are the incentives for industry?
  • Proposed diseases where development or improvement of vaccines would have a high impact on antibiotic use
  • Creating global vaccine research networks to pull resources and expertise to address gaps for priority diseases
Dr Andrew Potter
Veterinary
09:40

Advancements made in bacterial vaccines

  • Technologies for identification of antigens
  • Novel vaccine formulations
Dr Stéphane Lemiere
Veterinary
10:10

How early stage vaccine application aids decrease in the use of antibiotics, either for preventive or curative purposes in poultry

  • Benefits of early control in immunosuppressive poultry diseases
  • Application of vaccines at early stages of development, for example day 18 of age embryos for in ovo, or day old at hatch  
10:40

Networking coffee break

Panel discussion
Veterinary
11:30

Panel:Alternatives to Antibiotics: Issues and opportunities from funders’ perspective

  • How to incentivise vet pharma companies to produce new veterinary products to reduce AMR resistance
  • Marketing the science and the costs associated with this
  • Statement of societal goals that the funding entity would like to accomplish
  • Political feasibility of incentive mechanisms (e.g., is a program that gives money to large pharma companies likely to be accepted by legislators?)
  • Economics of incentive mechanisms (e.g., which incentive ‘lever’ can be pushed for maximal effect?  What would unintended consequences of such incentives be?)
12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 14/Dec/17 14:05

 

DOWNLOAD DRAFT AGENDA

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071